a Department of Oncology , Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore , MD , USA.
b Winship Cancer Institute , Emory University , Atlanta , GA , USA.
Autophagy. 2017 Aug 3;13(8):1386-1403. doi: 10.1080/15548627.2017.1332565. Epub 2017 Jul 11.
ADIPOQ/adiponectin, an adipocytokine secreted by adipocytes in the breast tumor microenvironment, negatively regulates cancer cell growth hence increased levels of ADIPOQ/adiponectin are associated with decreased breast cancer growth. However, its mechanisms of action remain largely elusive. We report that ADIPOQ/adiponectin induces a robust accumulation of autophagosomes, increases MAP1LC3B-II/LC3B-II and decreases SQSTM1/p62 in breast cancer cells. ADIPOQ/adiponectin-treated cells and xenografts exhibit increased expression of autophagy-related proteins. LysoTracker Red-staining and tandem-mCherry-GFP-LC3B assay show that fusion of autophagosomes and lysosomes is augmented upon ADIPOQ/adiponectin treatment. ADIPOQ/adiponectin significantly inhibits breast cancer growth and induces apoptosis both in vitro and in vivo, and these events are preceded by macroautophagy/autophagy, which is integral for ADIPOQ/adiponectin-mediated cell death. Accordingly, blunting autophagosome formation, blocking autophagosome-lysosome fusion or genetic-knockout of BECN1/Beclin1 and ATG7 effectively impedes ADIPOQ/adiponectin induced growth-inhibition and apoptosis-induction. Mechanistic studies show that ADIPOQ/adiponectin reduces intracellular ATP levels and increases PRKAA1 phosphorylation leading to ULK1 activation. AMPK-inhibition abrogates ADIPOQ/adiponectin-induced ULK1-activation, LC3B-turnover and SQSTM1/p62-degradation while AMPK-activation potentiates ADIPOQ/adiponectin's effects. Further, ADIPOQ/adiponectin-mediated AMPK-activation and autophagy-induction are regulated by upstream master-kinase STK11/LKB1, which is a key node in antitumor function of ADIPOQ/adiponectin as STK11/LKB1-knockout abrogates ADIPOQ/adiponectin-mediated inhibition of breast tumorigenesis and molecular analyses of tumors corroborate in vitro mechanistic findings. ADIPOQ/adiponectin increases the efficacy of chemotherapeutic agents. Notably, high expression of ADIPOQ receptor ADIPOR2, ADIPOQ/adiponectin and BECN1 significantly correlates with increased overall survival in chemotherapy-treated breast cancer patients. Collectively, these data uncover that ADIPOQ/adiponectin induces autophagic cell death in breast cancer and provide in vitro and in vivo evidence for the integral role of STK11/LKB1-AMPK-ULK1 axis in ADIPOQ/adiponectin-mediated cytotoxic autophagy.
ADIPOQ/脂联素,一种由乳腺肿瘤微环境中的脂肪细胞分泌的脂肪细胞因子,负向调节癌细胞生长,因此 ADIPOQ/脂联素水平的增加与乳腺癌生长的减少有关。然而,其作用机制在很大程度上仍不清楚。我们报告 ADIPOQ/脂联素诱导乳腺癌细胞中自噬体的大量积累,增加 MAP1LC3B-II/LC3B-II 并减少 SQSTM1/p62。ADIPOQ/脂联素处理的细胞和异种移植物表现出自噬相关蛋白的表达增加。溶酶体红色染色和串联 mCherry-GFP-LC3B 测定表明,自噬体与溶酶体融合在 ADIPOQ/脂联素处理后增强。ADIPOQ/脂联素在体外和体内均显著抑制乳腺癌的生长并诱导细胞凋亡,并且这些事件发生在巨自噬/自噬之前,这对于 ADIPOQ/脂联素介导的细胞死亡是必不可少的。因此,抑制自噬体的形成、阻断自噬体-溶酶体融合或基因敲除 BECN1/Beclin1 和 ATG7 可有效阻止 ADIPOQ/脂联素诱导的生长抑制和凋亡诱导。机制研究表明,ADIPOQ/脂联素降低细胞内 ATP 水平并增加 PRKAA1 磷酸化,从而导致 ULK1 激活。AMPK 抑制消除了 ADIPOQ/脂联素诱导的 ULK1 激活、LC3B 周转和 SQSTM1/p62 降解,而 AMPK 激活增强了 ADIPOQ/脂联素的作用。此外,ADIPOQ/脂联素介导的 AMPK 激活和自噬诱导受上游主激酶 STK11/LKB1 调节,STK11/LKB1 是 ADIPOQ/脂联素抗肿瘤功能的关键节点,因为 STK11/LKB1 敲除消除了 ADIPOQ/脂联素对乳腺癌发生的抑制作用,并且对肿瘤的分子分析证实了体外的机制发现。ADIPOQ/脂联素增加了化疗药物的疗效。值得注意的是,ADIPOQ 受体 ADIPOR2、ADIPOQ/脂联素和 BECN1 的高表达与接受化疗的乳腺癌患者总生存率的提高显著相关。总的来说,这些数据揭示了 ADIPOQ/脂联素在乳腺癌中诱导自噬性细胞死亡,并提供了体外和体内证据,证明 STK11/LKB1-AMPK-ULK1 轴在 ADIPOQ/脂联素介导的细胞毒性自噬中具有整体作用。